Please provide your email address to receive an email when new articles are posted on . Researchers from the University of Padova in Italy found that an antibiotic combination regimen of Merrem and ...

Cubist Pharmaceuticals Settles CUBICIN Patent Litigation with Teva Cubist grants Teva a license to sell generic daptomycin in US either as of June 24, 2018—if CUBICIN is granted pediatric exclusivity ...

* Cubicin clinically proven to target both Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) with equal efficacy[1] * These serious infections can cause death in up to ...

CUBICIN is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including ...

Please provide your email address to receive an email when new articles are posted on . Cubist Pharmaceuticals Inc.is voluntarily recalling one lot of Cubicin (daptomycin for injection) to the user ...

Reported earnings came in at 58 cents, compared to a loss of 34 cents in the year-ago quarter. The earnings results comfortably surpassed the Zacks Consensus Estimate of 48 cents. Results in the ...

cubicin packaging Merck announced the launch of Cubicin RF (daptomycin for injection), a new formulation of Cubicin. Merck announced the launch of Cubicin RF (daptomycin for injection), a new ...

Cubicin is a lipopeptide antibacterial indicated for complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections (bacteremia). Merck is recalling 1 lot of Cubicin ® ...

Dec 8 (Reuters) - Hospira Inc can launch a generic version of Cubist Pharmaceuticals Inc 's leading drug Cubicin as soon as 2016, a federal judge has ruled. U.S. District Judge Gregory Sleet in ...

The FDA has approved broader use for Cubist Pharmaceuticals’ Cubicin intravenous antibiotic to also treat bloodstream infections, including a form of endocarditis.Cubist plans to market Cubicin for ...

Swiss healthcare giant Novartis says that the European Commission has decided to expand use of the firm's antibiotic to treat two additional types of life-threatening hospital infections. Swiss ...

The Food and Drug Administration Thursday warned physicians and patients that the intravenous antibiotic Cubicin can cause life-threatening eosinophilic pneumonia, which is marked by the accumulation ...